Kaplan-Meier estimate

Kaplan-Meier estimate

(kap'lăn mī'ĕr),
nonparametric method of compiling life tables or survival tables that combines calculated probabilities of survival with estimates to allow for censored (missing) observations; used mainly in survival studies of cancer and similar long-term diseases.

Kap·lan-Mei·er es·ti·mate

(kap'lăn-mī'ĕr es'ti-măt)
Nonparametric method of compiling life tables or survival tables that combines calculated probabilities of survival with estimates to allow for censored (missing) observations; used mainly in survival studies of cancer and similar long-term diseases.
References in periodicals archive ?
Progression-free survival was not yet reached, but based on the Kaplan-Meier estimate, the progression-free survival rate at 18 months was 90%.
9 percent in the PTA group at one year based on Kaplan-Meier Estimate (p
A common mistake is to treat failures due to other causes as censored events and estimate the cumulative incidence function as the complement of the Kaplan-Meier estimate of the survival function.
about 14 weeks), according to a Kaplan-Meier estimate.
The absolute 5-year risk of nonfatal MI was 5%; the risk for MI or vascular death was 16%; and the risk for recurrent stroke, HI, or vascular death was 25%, according to a Kaplan-Meier estimate of survival.
The Kaplan-Meier estimate of survival was used to generate survivorship curves for endpoints of revision and component loosening.
The Kaplan-Meier estimate of the survivor function indicates that the median duration of exporting a product to the United States is very short, anywhere between two and four years.
The absolute 5-year risk of nonfatal MI was 5%; the risk for MI or vascular death was 16%; and the risk for recurrent stroke, MI, or vascular death was 25%, according to a Kaplan-Meier estimate of survival.
Most of the patients (61%) had no symptoms at the time of diagnosis, but 62% had symptoms of pruritis or fatigue within 5 years; only 5% had no symptoms after 20 years, according to a Kaplan-Meier estimate (Gastroenterology 123[4]:1044-51, 2002).
In patients without prior antiangiogenic therapy, progression-free survival at 6 months (PFS6) assessed by Kaplan-Meier estimate was 25%, with a 30% rate of censoring at the time of analysis.
The Kaplan-Meier estimate for the median duration of response was 287 days, or 9.
In addition, the median duration of response reported above is a Kaplan-Meier estimate based on the length of follow up for all responders at the time the PROPEL trial database was locked.